http://www.nibr.com/rss/NIBR-Stories-EN.xml Find the latest news about NIBR. http://www.nibr.com/images/_common/nibr-logo-new.gif http://www.nibr.com May-10-2013 en-us http://nibr.com/newsroom/stories/2013/2013May10_Huntingtons-Disease.shtml May-10-2013 Work by NIBR researchers in mice suggests that targeting protein NUB1, which plays a role in controlling protein degradation, could reduce cell death. http://nibr.com/newsroom/stories/2013/2013Mar22_HorseVirus.shtml Mar-22-2013 The Exploratory Virology group in Emeryville organized recently to discover previously unknown viruses that cause disease. The first one they may have unraveled is a mysterious 100 year old horse virus. The news was featured in Nature. http://nibr.com/newsroom/stories/2013/2013Feb22_RareDiseases.shtml Mar-01-2013 Rare diseases are a key focus of the research strategy at the Novartis Institutes for BioMedical Research (NIBR) where scientists are currently investigating treatments for more than 40 rare diseases. http://nibr.com/newsroom/stories/2013/2013Feb08_MedicalNeedInGhana.shtml Feb-08-2013 Building connections between NIBR and African scientists and medical communities is critical to solving major health problems that impact millions of people in Africa. By building scientific and medical capabilities in these countries, local scientists and physicians can more effectively address the health of their own populations. One effort is underway with University of Science and Technology (KNUST) in Kumasi, Ghana. http://nibr.com/newsroom/stories/2012/2012Nov05_NGS.shtml Nov-05-2012 NIBR Scientists are using Next Generation Sequencing to map networks of cellular signaling pathways and identify and modulate key spots or targets to correct imbalances in the system and treat disease. http://nibr.com/newsroom/stories/2012/2012Oct05_Novartis-Science-Top-20-Employers.shtml Oct-05-2012 Novartis is again among the top companies on the 2012 Science Top 20 Employers' list. This year, key drivers in the magazine's flagship ranking included innovation, social responsibility, and an understanding that important quality research is underway. http://nibr.com/newsroom/stories/2012/2012Sep14_NIBR-Recruitment.shtml Sep-19-2012 The NIBR Next Generation Diagnostics group now being recruited in Cambridge will use next generation sequencing and other cutting-edge molecular characterization technologies to discover breakthrough therapeutics. http://nibr.com/newsroom/stories/2012/2012Aug17_NIBR-Kenyatta-University.shtml Aug-20-2012 Medicinal chemist Heather Burks and computational chemist Lewis Whitehead didn't foresee a trip to Kenya as part of their job descriptions until they participated in the NIBR-Seeding Labs Scientific Fellowship Program, piloted in 2010. http://nibr.com/newsroom/stories/2012/2012July27_NIBR-Community.shtml Aug-02-2012 Novartis is committed to being a good corporate citizen and supports local communities in a multitude of ways. From sewing pillowcases for cancer patients to preparing educational materials for local children, associates are enthusiastic to get involved. http://nibr.com/newsroom/stories/2012/2012July13_NIBR-Energy-Efficiency.shtml Jul-13-2012 Nominated by NSTAR/Northeast Utilities in the US, NIBR was honored for outstanding achievements in energy efficiency which have resulted in annual energy savings of over 4000 MWh, and cost savings of over $600,000 every year. http://nibr.com/newsroom/stories/2012/2012June29_The-Scientist-Survey.shtml Jun-29-2012 Novartis is one of only four big pharma companies on The Scientist's top 20 Best Places to Work list in 2012. Scientists highlighted training and development and remuneration and benefits as key strengths. http://nibr.com/newsroom/stories/2012/2012Jun15_Drug-ADR.shtml Jun-15-2012 NIBR- UCSF computer model detects adverse side effects before pesky drug-candidates get too far along. http://www.nibr.com/newsroom/stories/2012/2012Jun08_NIBR-Shanghai-En-Li.shtml Jun-08-2012 En Li, Head of NIBR Shanghai, embarks on a journey to develop a drug discovery research site dedicated to improving his home country's healthcare. http://www.nibr.com/newsroom/stories/2012/2012May18_PoCPromisingMedicine.shtml May-18-2012 Novartis has one of the strongest pipelines in the industry that start with NIBR proof of concept(PoC) studies. Read about two of the 12 that advanced to the clinic in 2011. http://www.nibr.com/newsroom/stories/2012/2012Apr13_CAGroundbreaking.shtml Apr-13-2012 Renowned designers and architects Maya Lin and Toshiko Mori joined Mark Fishman, President of the Novartis Institutes for BioMedical Research, the Governor of Massachusetts and other notables Thursday, April 12, 2012 to break ground on a 550,000 square foot campus of lab, office and retail space across the street from the global headquarters for the Novartis Institutes for BioMedical Research (NIBR). http://www.nibr.com/newsroom/stories/2012/2012Apr06_CellLineEncyclopedia.shtml Apr-06-2012 A collaboration between NIBR and the Broad Institute yields a comprehensive encyclopedia of genetic information and drug sensitivity for hundreds of cancer cell lines. http://www.nibr.com/newsroom/stories/2012/2012Mar09_MolecularPathways.shtml Mar-09-2012 Watch what NIBR scientists have to say about how their focus on molecular pathways is changing the way we look at disease. http://www.nibr.com/newsroom/stories/2012/2012Jan20_ChagasScience.shtml Feb-17-2012 Mammalian cells become increasingly filled with proliferating T cruzi parasites during cell culture. Image shown is after 8 days of infection. Parasites are visualized as smaller, yellow/ green dots surrounding the mammalian nuclei. http://www.nibr.com/newsroom/stories/2012/2012Jan20_ChagasPeople.shtml Feb-17-2012 Researchers working across NIBR are tackling this important disease. http://nibr.com/newsroom/stories/2012/2012Jan13_MFishman10Years.shtml Jan-13-2012 Mark Fishman started heading up research and development at Novartis, as President of the Novartis Institutes for BioMedical Research (NIBR), 10 years ago. http://nibr.com/newsroom/stories/2011/2011Dec15_EarlyCareerAward.shtml Dec-18-2011 Professor David Chen, Seoul National University and Professor David Spiegel, Yale University received the 2011 Novartis Early Career Award in Organic Chemistry. http://nibr.com/newsroom/stories/2011/2011Nov18_Malaria-Tools.shtml Nov-17-2011 NIBR, along with collaborators, discovered a new class of dual-acting antimalarial compounds that target both liver- and blood-infections - the imidazolopiperazines (IZPs). http://nibr.com/newsroom/stories/2011/2011Nov11_Innovative-Culture.shtml Nov-11-2011 If you ask associates at Novartis Institutes for BioMedical Research (NIBR) what energizes them about the organization, they are likely to describe our strategic approach to drug discovery - focus on unmet medical need of patients worldwide in areas where we understand the mechanism of disease. It has resulted in one of the leading pipelines in the pharmaceutical industry today, continually reinforced by a culture that demands innovation. http://nibr.com/newsroom/stories/2011/2011Oct21_Typhoid_Vaccine_ClinicalTrial.shtml Oct-24-2011 Pakistani health authorities and a NVGH Pakistani scientist collaborate to bring a typhoid-fever-vaccine clinical trial to the region. http://nibr.com/newsroom/stories/2011/2011Oct07_DonaldGanem.shtml Oct-07-2011 NIBR cements its position as a hub of innovative research in the Bay Area by establishing Infectious Disease (ID) Headquarters in Emeryville, led by Don Ganem. http://nibr.com/newsroom/stories/2011/2011Sept23_JobDiscovering.shtml Sept-23-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://www.nibr.com/newsroom/stories/2011/2011Sept02_Imaging.shtml Sept-03-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://nibr.com/newsroom/stories/2011/2011Aug04_GraziaPiizzi.shtml Aug-09-2011 The NIBR Developing World Mini-Sabbatical Program combines a scientific sabbatical combined with social impact. Grazia Piizzi, a NIBR investigator in Global Discovery Chemistry- Oncology and Exploratory Chemistry, demonstrates the program's exponential value. http://nibr.com/newsroom/stories/2011/2011Jun10_JobCandidatesViaTwitter.shtml Jun-06-2011 "A 2010 survey conducted by Jobvite, a social search platform for recruitment, showed that 83% of recruiting professional are now using or are planning to use social media for recruiting; social network recruiting is gaining momentum," said Harold Mellor, associate director of staffing and NIBR Jobs Tweeter. http://www.nibr.com/newsroom/stories/2011/2011May13_ScientistBestPlace.shtml May-06-2011 "By forging new relationships and finding novel uses for existing technologies, (Novartis) is among this year's top companies that are finding creative ways to advance science," according to The Scientist. http://nibr.com/newsroom/stories/index.shtml April-29-2011 Dramatic shifts in the size of global, ethnic and regional populations are expected during the next 50 years. The Novartis Institutes for BioMedical Research (NIBR) is holding its inaugural Health Equity Symposium May 3-4, which will gather scientists, clinicians and policymakers to discuss what industry, academia and government can do to help shape the way biomedical research is conducted. The goal is to better serve the unique needs of each group and ensure a more equitable delivery of health care. Leading researchers and policymakers, including Dr. Julio Frenk, Dean, Harvard School of Public Health and Mexico's former Minister of Health, are among the speakers. The symposium will be webcast live, then archived for later viewing. http://nibr.com/downloads/newsroom/resources/PoC2010_0405_e.pdf April-22-2011 At the Novartis Institutes for BioMedical Research (NIBR), the primary objective of a Proof of Concept (PoC) study is to test hypotheses of how a drug may work in the body and to expedite the generation of clinical evidence regarding patient benefit. NIBR had 12 PoCs in 2010. Several outlined here illustrate NIBR's pathways approach to drug discovery. http://nibr.com/newsroom/stories/2011/2011Mar11_PostDocstoScientist.shtml Mar-11-2011 Offering health, retirement, relocation and many other benefits, Novartis' postdoctoral programs around the world consistently rank among the Best Places to Work. http://nibr.com/newsroom/stories/2011/2011Mar03_BillSellers.shtml Mar-03-2011 Bill Sellers, Global Head of Oncology since 2005, has been named to the National Cancer Advisory Board (NCAB). Previously with Harvard Medical School and the Dana Farber Cancer Institute, Bill was named, February 24th by the White House. http://nibr.com/newsroom/stories/2011/2011Feb07_GenomicsInstitute.shtml Feb-07-2011 GNF in La Jolla, California, USA was founded in 1999 on the back of the genomics revolution. At that time, sequencing the human genome was a hot scientific goal, and GNF was created to develop genomics-based technology and associated basic research. In 2002, the GNF Board of Directors made the decision to apply the tools and expertise developed there to exploit the human genome effort in the pursuit of drug discovery. The Institute still has a commitment to basic research and technology development, and it is focused on identifying pathways and targets that are relevant to human disease. All technologies that are developed are done with an eye toward enabling biological discovery or accelerating the drug discovery process. http://nibr.com/newsroom/stories/2011/2011Jan14_EpigeneticsPostDoc.shtml Jan-14-2011 The Novartis Institutes for BioMedical Research (NIBR) in collaboration with the Friedrich Miescher Institute (FMI - a research institute of NIBR) in Basel, Switzerland has a variety of postdoctoral positions in the area of epigenetics, focusing on the interface with regenerative medicine, neuroscience, etiology of cancer and immune disorders, and structural biology. http://nibr.com/newsroom/stories/2011/2011Jan05_AFQ056.shtml Jan-05-2011 The Novartis Institutes for BioMedical Research (NIBR) in collaboration with the Friedrich Miescher Institute (FMI - a research institute of NIBR) in Basel, Switzerland has a variety of postdoctoral positions in the area of epigenetics, focusing on the interface with regenerative medicine, neuroscience, etiology of cancer and immune disorders, and structural biology.